Request a Premium Quote

Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines

In Brief This Week: Day One, Sophia Genetics, Genetron Health, Global Cancer Technology

Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent

Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues

Blueprint Medicines Q2 Revenues Increase More Than 200 Percent

Merck Q2 Revenues Grow 22 Percent